Definition and epidemiology
Insomnia disorder is defined by persistent difficulty with sleep initiation, duration, consolidation, or quality, occurring despite adequate opportunity and circumstances for sleep, and resulting in daytime impairment (fatigue, mood disturbance, poor concentration, reduced performance).
- Acute (short-term) insomnia: lasts less than 3 months, often tied to an identifiable stressor.
- Chronic insomnia disorder: symptoms occur at least 3 nights per week for 3 months or longer (DSM-5 and ICSD-3 criteria).
It is one of the most common complaints in primary care. Approximate prevalence of chronic insomnia in adults is 10%, with transient insomnia symptoms reported by up to 30-50% of adults at some point. Prevalence increases with age and is roughly 1.5-2 times more common in women than men. Comorbid psychiatric and medical disease is present in a large proportion of chronic cases, which is why insomnia is now classified as a distinct disorder rather than always secondary to another condition.
- Chronic insomnia requires symptoms ≥3 nights/week for ≥3 months with daytime impairment.
- CBT-I, not medication, is first-line treatment per major guidelines.
- Sleep restriction and stimulus control are the core behavioral components of CBT-I.
- Polysomnography is not routinely needed; reserve for suspected OSA, PLMD, or narcolepsy.
- The 3P model (predisposing, precipitating, perpetuating) explains why acute insomnia becomes chronic.
- Hyperarousal (elevated cortisol, increased EEG beta activity) is the leading pathophysiologic model.
- Benzodiazepines and Z-drugs are for short-term use only due to dependence and fall risk.
- Always screen for and treat comorbid depression, anxiety, and OSA.
Etiology and risk factors
Insomnia is multifactorial; most chronic cases involve a combination of predisposing, precipitating, and perpetuating factors (the 3P model).
Predisposing factors
- Female sex, older age
- Family history of insomnia
- Trait anxiety, tendency toward hyperarousal
Precipitating factors
- Acute stress (work, bereavement, illness)
- Medical illness (chronic pain, cardiopulmonary disease, hyperthyroidism, GERD, menopause)
- Psychiatric illness (major depression, generalized anxiety disorder, PTSD)
- Medications and substances (caffeine, alcohol, nicotine, stimulants, corticosteroids, SSRIs, decongestants)
- Other sleep disorders (obstructive sleep apnea, restless legs syndrome, circadian rhythm disorders)
Perpetuating factors
- Maladaptive behaviors: extended time in bed, daytime napping, irregular sleep schedule
- Conditioned arousal: the bed/bedroom becomes associated with wakefulness and frustration
- Excessive worry about sleep loss itself
Pathophysiology
The leading model is hyperarousal: increased cognitive, emotional, and physiologic activation that prevents normal sleep onset and maintenance. Evidence includes elevated cortisol and ACTH levels, increased metabolic rate, elevated body temperature, and increased high-frequency EEG activity (beta/gamma) during sleep in people with chronic insomnia.
The 3P model (Spielman) explains chronicity: an individual with predisposing vulnerability experiences a precipitating event that triggers acute insomnia; perpetuating behaviors (compensatory time in bed, irregular schedules, sleep-related anxiety) then maintain the problem long after the original trigger resolves. This is the conceptual basis for CBT-I, which directly targets perpetuating factors.
Clinical features
- Difficulty falling asleep (sleep-onset insomnia)
- Frequent or prolonged nighttime awakenings (sleep-maintenance insomnia)
- Early morning awakening with inability to return to sleep
- Perception of poor sleep quality despite adequate time in bed
- Daytime consequences: fatigue, irritability, impaired concentration/memory, mood disturbance, reduced work or social performance, increased error/accident risk
Symptoms must occur despite adequate opportunity for sleep (ruling out voluntary sleep restriction) and cause distress or functional impairment.
Diagnosis
Insomnia is primarily a clinical diagnosis based on history.
Diagnostic criteria (DSM-5 / ICSD-3, summarized)
- Dissatisfaction with sleep quantity or quality, with one or more of: difficulty initiating sleep, difficulty maintaining sleep, early morning awakening
- Occurs ≥3 nights/week for ≥3 months (chronic) despite adequate opportunity for sleep
- Causes clinically significant distress or impairment in daytime functioning
- Not better explained by another sleep-wake disorder, and not solely due to a substance
Workup
- Detailed sleep history: onset, duration, pattern, sleep hygiene, caffeine/alcohol/medication use, screen time
- Sleep diary for 1-2 weeks is the standard initial tool
- Screen for depression, anxiety, and other psychiatric disease
- Screen for other sleep disorders (snoring/apneas suggest obstructive sleep apnea; leg discomfort suggests restless legs syndrome)
- Polysomnography is NOT routine; reserved for suspected sleep apnea, periodic limb movement disorder, narcolepsy, or when diagnosis is unclear
- Actigraphy can supplement but is not required
- Basic labs (TSH, CBC) if clinical suspicion of an underlying medical cause
Differential diagnosis
| Condition | Distinguishing feature |
|---|---|
| Obstructive sleep apnea | Loud snoring, witnessed apneas, obesity, daytime sleepiness rather than difficulty falling asleep |
| Restless legs syndrome | Uncomfortable urge to move legs, worse at rest/evening, relieved by movement |
| Circadian rhythm sleep-wake disorder | Normal sleep quality but at the wrong time (e.g., delayed sleep phase in adolescents) |
| Major depressive disorder | Early morning awakening, low mood, anhedonia; insomnia may be secondary |
| Generalized anxiety disorder | Prominent worry, muscle tension, sleep-onset difficulty tied to rumination |
| Substance-induced sleep disorder | Temporal relationship to caffeine, alcohol, stimulant, or withdrawal |
| Inadequate sleep hygiene / voluntary sleep restriction | Sleep is adequate when opportunity is given (e.g., weekends) |
Management
First-line: Cognitive behavioral therapy for insomnia (CBT-I)
Recommended as first-line treatment by the American College of Physicians, American Academy of Sleep Medicine, and European Sleep Research Society guidelines. Components include:
- Sleep restriction therapy: limits time in bed to match actual sleep time, then gradually titrates
- Stimulus control: use the bed only for sleep (and sex); leave bed if unable to sleep after ~20 minutes
- Cognitive therapy: addresses dysfunctional beliefs/worry about sleep
- Relaxation training
- Sleep hygiene education (adjunct only, not sufficient alone): regular schedule, limit caffeine/alcohol/nicotine, limit screens before bed, comfortable sleep environment
Digital/self-guided CBT-I programs are effective alternatives when in-person therapy is unavailable.
Pharmacotherapy
Considered when CBT-I is unavailable, insufficient, or for short-term/adjunct use. Guidelines generally favor short-term use at the lowest effective dose.
- Dual orexin receptor antagonists (e.g., suvorexant, lemborexant) — increasingly favored, improved safety profile
- Melatonin receptor agonist (ramelteon) — useful for sleep-onset insomnia, low abuse potential
- Nonbenzodiazepine "Z-drugs" (zolpidem, zaleplon, eszopiclone) — effective but risk of dependence, next-day sedation, parasomnias
- Benzodiazepines (e.g., temazepam) — generally avoided for routine use given dependence/fall risk, especially in older adults
- Low-dose sedating antidepressants (trazodone, doxepin at low dose) — sometimes used off-label
- Melatonin (OTC) — modest evidence, mainly helpful for circadian-related sleep-onset difficulty
Antihistamines (e.g., diphenhydramine) are commonly used OTC but are generally discouraged due to anticholinergic side effects and minimal evidence of benefit, particularly in older adults.
General principles
- Treat underlying contributing conditions (depression, anxiety, OSA, pain, hyperthyroidism)
- Avoid long-term benzodiazepine/Z-drug use; reassess regularly if prescribed
- CBT-I and pharmacotherapy can be combined, though CBT-I effects tend to be more durable
Complications and prognosis
Chronic insomnia is associated with:
- Increased risk of major depressive disorder and anxiety disorders (bidirectional relationship)
- Impaired work performance, increased absenteeism, and higher accident/injury risk (including motor vehicle accidents)
- Reduced quality of life
- Possible association with hypertension and metabolic dysfunction, though causality is debated
With CBT-I, a majority of patients experience significant and durable improvement, often outlasting pharmacotherapy effects after treatment discontinuation. Untreated chronic insomnia tends to persist and fluctuate with stress and comorbid illness over time.
3P's of chronic insomnia: Predisposing, Precipitating, Perpetuating factors.
Practice questions
1. A 45-year-old woman reports 4 months of difficulty falling asleep most nights, taking over an hour to fall asleep despite feeling tired. She reports daytime fatigue and irritability affecting her work. She has no snoring, witnessed apneas, or leg discomfort. Physical exam and TSH are normal. Which of the following is the most appropriate first-line treatment?
2. A 68-year-old man with chronic insomnia has been using zolpidem nightly for 2 years. His daughter brings him in after he fell at night while walking to the bathroom. Which of the following best explains this complication?
3. A 30-year-old man reports several weeks of trouble staying asleep, waking at 3 AM with racing thoughts about work deadlines, and difficulty returning to sleep. He also describes excessive worry, muscle tension, and difficulty concentrating during the day for the past 8 months. Which underlying condition should be most strongly considered?
Frequently asked questions
What causes insomnia?
Insomnia results from a combination of predisposing traits (anxiety, female sex, family history), a precipitating stressor (illness, grief, work stress), and perpetuating behaviors (napping, irregular schedules, worry about sleep) that maintain the problem. Underlying medical or psychiatric conditions, medications, caffeine, and other sleep disorders like sleep apnea can also directly cause or worsen insomnia.
What are the first symptoms of insomnia?
The earliest symptoms are difficulty falling asleep, frequent nighttime awakenings, or waking too early and being unable to fall back asleep. These are typically followed by daytime symptoms such as fatigue, irritability, poor concentration, and reduced performance at work or school, which is what usually prompts people to seek care.
How is insomnia diagnosed?
Insomnia is diagnosed clinically through a detailed sleep history and often a 1-2 week sleep diary, without routine need for sleep lab testing. Diagnosis requires difficulty initiating or maintaining sleep at least 3 nights per week for 3 months, causing significant distress or daytime impairment, despite adequate opportunity to sleep. Polysomnography is reserved for suspected additional sleep disorders like sleep apnea.
Is insomnia curable?
Chronic insomnia is highly treatable, and many patients achieve lasting remission with cognitive behavioral therapy for insomnia (CBT-I), which has more durable effects than medication alone. It is not always a one-time cure, since insomnia can recur with stress or illness, but most people see significant, sustained improvement in sleep quality and daytime functioning with proper treatment.
Insomnia vs obstructive sleep apnea — what is the difference?
Insomnia is difficulty falling asleep or staying asleep, often with trouble feeling rested despite adequate time in bed, while obstructive sleep apnea involves repeated airway obstruction during sleep causing loud snoring, witnessed breathing pauses, and excessive daytime sleepiness rather than difficulty initiating sleep. The two can coexist, and OSA should be screened for in patients with risk factors like obesity or loud snoring before attributing symptoms solely to insomnia.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: F51.0
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.